About Quarterly Earnings Report Disclosures
| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥124.39B | ¥119.99B | +3.7% |
| Cost of Sales | ¥88.02B | ¥87.30B | +0.8% |
| Gross Profit | ¥36.38B | ¥32.69B | +11.3% |
| SG&A Expenses | ¥34.05B | ¥31.73B | +7.3% |
| Operating Income | ¥2.33B | ¥956M | +143.3% |
| Non-operating Income | ¥488M | ¥468M | +4.3% |
| Non-operating Expenses | ¥2.51B | ¥2.68B | -6.5% |
| Ordinary Income | ¥305M | ¥-1.26B | +124.3% |
| Profit Before Tax | ¥-187M | ¥-1.57B | +88.1% |
| Income Tax Expense | ¥-329M | ¥-749M | +56.1% |
| Net Income | ¥142M | ¥-821M | +117.3% |
| Net Income Attributable to Owners | ¥205M | ¥-821M | +125.0% |
| Total Comprehensive Income | ¥1.43B | ¥-2.83B | +150.5% |
| Depreciation & Amortization | ¥10.77B | ¥9.94B | +8.3% |
| Interest Expense | ¥343M | ¥238M | +44.1% |
| Basic EPS | ¥3.61 | ¥-14.47 | +124.9% |
| Diluted EPS | ¥3.61 | - | - |
| Dividend Per Share | ¥62.00 | ¥62.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥118.06B | ¥119.14B | ¥-1.08B |
| Cash and Deposits | ¥39.56B | ¥40.88B | ¥-1.32B |
| Accounts Receivable | ¥47.88B | ¥46.62B | +¥1.26B |
| Inventories | ¥6.46B | ¥5.58B | +¥880M |
| Non-current Assets | ¥155.90B | ¥160.37B | ¥-4.47B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥6.22B | ¥6.67B | ¥-443M |
| Financing Cash Flow | ¥-5.82B | ¥10.67B | ¥-16.49B |
| Item | Value |
|---|---|
| Book Value Per Share | ¥2,374.29 |
| Net Profit Margin | 0.2% |
| Gross Profit Margin | 29.2% |
| Current Ratio | 177.5% |
| Quick Ratio | 167.8% |
| Debt-to-Equity Ratio | 1.03x |
| Interest Coverage Ratio | 6.78x |
| EBITDA Margin | 10.5% |
| Effective Tax Rate | 175.9% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +3.7% |
| Operating Income YoY Change | +143.2% |
| Ordinary Income YoY Change | +26.5% |
| Net Income Attributable to Owners YoY Change | +153.5% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 57.48M shares |
| Treasury Stock | 656K shares |
| Average Shares Outstanding | 56.82M shares |
| Book Value Per Share | ¥2,378.06 |
| EBITDA | ¥13.09B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥62.00 |
| Year-End Dividend | ¥63.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| ClinicalLabTesting | ¥249M | ¥-930M |
| InVitroDiagnostics | ¥1.99B | ¥4.83B |
| SterilizationAndRelatedServices | ¥90M | ¥1.16B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥252.00B |
| Operating Income Forecast | ¥8.00B |
| Ordinary Income Forecast | ¥6.00B |
| Net Income Attributable to Owners Forecast | ¥7.00B |
| Basic EPS Forecast | ¥124.68 |
| Dividend Per Share Forecast | ¥63.00 |
This data was automatically extracted from XBRL files. Please refer to the original disclosure documents for accuracy.
| Property, Plant & Equipment | ¥70.71B | ¥73.55B | ¥-2.84B |
| Intangible Assets | ¥43.03B | ¥44.28B | ¥-1.25B |
| Goodwill | ¥9.96B | ¥7.68B | +¥2.28B |
| Investment Securities | ¥789M | ¥1.80B | ¥-1.01B |
| Total Assets | ¥274.02B | ¥279.58B | ¥-5.56B |
| Current Liabilities | ¥66.50B | ¥69.44B | ¥-2.94B |
| Accounts Payable | ¥19.10B | ¥18.91B | +¥194M |
| Short-term Loans | ¥10.00B | ¥10.00B | ¥0 |
| Non-current Liabilities | ¥72.39B | ¥72.85B | ¥-461M |
| Long-term Loans | ¥19.16B | ¥19.18B | ¥-21M |
| Total Liabilities | ¥138.89B | ¥142.29B | ¥-3.40B |
| Total Equity | ¥135.13B | ¥137.29B | ¥-2.17B |
| Capital Stock | ¥9.29B | ¥9.28B | +¥8M |
| Capital Surplus | ¥25.10B | ¥25.09B | +¥9M |
| Retained Earnings | ¥89.91B | ¥93.31B | ¥-3.40B |
| Treasury Stock | ¥-2.26B | ¥-2.26B | ¥-1M |
| Owners' Equity | ¥134.91B | ¥137.01B | ¥-2.10B |
| Working Capital | ¥51.56B | - | - |